The Illnesses of Unknown Etiology section aims to provide a translational medicine forum for the publication of research on illnesses, multi-system diseases and syndromes of unknown etiology.
Edited by Monica C. Panelli, the section welcomes research on all aspects of ME/CFS and multi-system diseases of unknown cause with applications in medicine and biotechnology, as well as contributions that employ traditional clinical, metabolic, epidemiologic, genomics and proteomics methods as diagnostic and prognostic tools.
Read the latest articles in the Illnesses of Unknown Etiology section
The tumor-promoting role of tumor microenvironment (TME) in colorectal cancer has been widely investigated in cancer biology. Cancer-associated fibroblasts (CAFs), as the main stromal component in TME, play an important role in promoting tumor progression and metastasis. Some studies have identified different types of CAFs at the single-cell level according to unique gene signatures or functions. However, the types and functions of CAFs varies in different studies or tumor types, suggesting that the functional roles of CAFs in TME is complicated and yet has not been clearly explained.
In this article, Peng and colleagues explored the corsstalk between CAFs and microenvironment in the pathogenesis of colorectal cancer in order to provide basis for precision therapy. Two types of CAFs were identified using integrated data and researchers explored the functional significance of TME.
According to the involvement of microbiota in modulating physiological processes, any alteration in its composition and diversity has been linked to a variety of pathologies, including cancer. In this bidirectional relationship, colonization with various bacterial species is correlated with a reduced or elevated risk of certain cancers. Notably, the gut microflora could potentially play a direct or indirect role in tumor initiation and progression by inducing chronic inflammation and producing toxins and metabolites. Therefore, identifying the bacterial species involved and their mechanism of action could be beneficial in preventing the onset of tumors or controlling their advancement. Likewise, the microbial community affects anti-cancer approaches’ therapeutic potential and adverse effects.
In this review, Sadrekarimi et al summarize the evidence revealing the microbiota's involvement in cancer and its mechanism, and also delineated how microbiota could predict colon carcinoma development or response to current treatments to improve clinical outcomes.
Journal of Translational Medicine has launched In Review, a new option that provides authors with on-demand information on the status of their manuscript, enables them to share their work with funders and their research community, and allows their colleagues to comment and collaborate - all whilst their manuscript is under review.
Read MoreGet to know the Editors behind Journal of Translational Medicine!
Please note that Journal of Translational Medicine is no longer considering submissions of study protocols.
Check out last month's top 20 most discussed articles from Journal of Translational Medicine!
nadia_buravleva / stock.adobe.com
Journal of Translational Medicine would like to warmly thank the top reviewers whose comments helped to shape the journal, for their assistance with review of manuscripts in Volume 18 (2020).
Translational Medicine Communications. the companion journal to Journal of Translational Medicine, is an interdisciplinary forum for all scientifically valid research from across translational medicine.
The journal aims to improve transparency and reproducibility within translational medicine and considers research papers regardless of outcome or significance of findings.
Led by Section Editor Salvatore Nesci, this new section aims to promote the translation of basic research emerging from biochemistry, molecular medicine, physiology and biotechnology into cell metabolism in order to be exploited in clinical applications.
Cellular Metabolism Therapy will consider research that covers any aspect of translational metabolic research, including (but not limited to): genetic disorders and epigenetic diseases; metabolic derangements causing neurodegeneration; immunometabolism; stroke; cardiovascular diseases; tumours; stem cell bioenergetics; ageing; carbohydrate, lipid, and protein metabolism.
Led by Section Editor Marcello Maggiolini, this exciting new section is dedicated to uncovering pivotal transduction signaling involved in pathophysiological processes toward a translational impact on the discovery of novel targets and therapeutics.
Translational Signaling and System Biology section welcomes articles providing new mechanistic insights on a broad range of fields, drug action through new formulations and delivery methods, novel cellular and animal models, computational and systems biology, and innovative laboratory concepts fostering translational research from the bench to the bedside.
Led by Section Editor Giuseppe Intini, this new section aims to foster new discoveries in the field of Craniofacial and Dental Medicine. It is interested in interested in research that investigates innovative approaches in all craniofacial and dental specialties, including oral medicine and oral pathology.
Translational Craniofacial and Dental Medicine will consider studies regarding therapeutic approaches for treatment of diseases and for tissue regeneration, biomaterials for restorative prosthesis and implantology, diagnostic tools, imaging, and large data analysis. Translational genomics and precision medicine studies that identify novel prognostic markers, tailored interventions, and prophylactic approaches are also welcome.
Led by Section Editor Claire Vanpouille-Box, this new section is interested in innovative research that investigate the crosstalk between ionizing radiations (IR), the tumor microenvironment (TME) and host immunity.
Studies considered for publication include (but not limited to) those investigating the mechanisms of radiation-induced anti-tumor immune responses, the immune-stimulatory and immuno-suppressive properties of ionizing radiation from all sources, biomarkers predictive of immune response, immune escape mechanisms elicited by IR and radioresistance. Importantly, the section welcomes translational and clinical studies assessing the combination of IR with immunotherapies (IT) with an emphasis on clinical response and outcome.
Dr. Marincola received his MD, summa cum laude from the University of Milan, Italy and Surgery training at Stanford University, California. His research interest lies in translational medicine and focuses on the development of strategies for the dynamic study of patients’ response to immunotherapy. His approach has brought seminal observations regarding the mechanisms leading to rejection of tumors, allograft rejection, graft-versus-host disease and autoimmunity.
Dr. Marincola is currently Global Head of Research at Kite Pharma, Santa Monica, California. He previously was President and Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California, Distinguished Research Fellow at AbbVie Corporation in Redwood City, California, Chief Research Officer at Sidra Medical and Research Center in Doha Qatar and Tenured Investigator at the National Institutes of Health, Bethesda Maryland. Dr. Marincola founded in 2003 the Journal of Translational Medicine of which he is currently the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications. He is past-president of the Society for the Immunotherapy of Cancer (SITC) and of the International Society for Translational Medicine. Dr. Marincola is editor of several biomedical books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook. Dr. Marincola is an award winning fiction writer author of The Wise Men of Pizzo and the Cat Behind the Window.
Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.
The journal covers all areas of translational medicine but also has several special sections:
|
|
|
Citation Impact
8.440 - 2-year Impact Factor (2021)
7.552 - 5-year Impact Factor (2021)
1.582 - Source Normalized Impact per Paper (SNIP)
1.570 - SCImago Journal Rank (SJR)
Speed
8 days to first decision for all manuscripts (Median)
96 days to first decision for reviewed manuscripts only (Median)
Usage
4,155,992 Downloads (2021)
7,409 Altmetric mentions (2021)